Canopy Growth Corporation (CGC)

$7.83

+1.34

(+20.65%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Canopy Growth Corporation

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 108.72M → 78.50M (in $), with an average decrease of 14.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -310.01M → -216.79M (in $), with an average increase of 43.0% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 33.0% return, outperforming this stock by 87.6%

  • Vs NBIX

    In the last 3 years, Canopy Growth Corporation has experienced a drawdown of -97.7%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 48.3%

Performance

  • $6.45
    $8.19
    $7.83
    downward going graph

    17.62%

    Downside

    Day's Volatility :21.23%

    Upside

    4.38%

    downward going graph
  • $2.76
    $19.20
    $7.83
    downward going graph

    64.75%

    Downside

    52 Weeks Volatility :85.63%

    Upside

    59.22%

    downward going graph

Returns

PeriodCanopy Growth CorporationSector (Health Care)Index (Russel 2000)
3 Months
46.17%
-0.7%
0.0%
6 Months
8.91%
6.6%
0.0%
1 Year
-54.62%
3.7%
-1.5%
3 Years
-97.64%
14.0%
-21.8%

Highlights

Market Capitalization
636.0M
Book Value
$6.57
Earnings Per Share (EPS)
-15.48
Wall Street Target Price
4.36
Profit Margin
0.0%
Operating Margin TTM
-31.75%
Return On Assets TTM
-8.89%
Return On Equity TTM
-121.56%
Revenue TTM
362.2M
Revenue Per Share TTM
5.59
Quarterly Revenue Growth YOY
-7.5%
Gross Profit TTM
-81.9M
EBITDA
-245.7M
Diluted Eps TTM
-15.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.95
EPS Estimate Next Year
-0.98
EPS Estimate Current Quarter
-0.37
EPS Estimate Next Quarter
-0.34

Analyst Recommendation

Sell
    5%Buy
    40%Hold
    55%Sell
Based on 20 Wall street analysts offering stock ratings for Canopy Growth Corporation(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
8
8
8
Sell
11
12
12

Analyst Forecast

What analysts predicted

Downside of 44.32%

Current $7.83
Target $4.36

Company Financials

FY18Y/Y Change
Revenue
77.9M
↑ 95.38%
Net Income
-54.1M
↑ 225.97%
Net Profit Margin
-69.45%
↓ 27.82%
FY19Y/Y Change
Revenue
169.6M
↑ 190.37%
Net Income
-502.1M
↑ 1137.84%
Net Profit Margin
-296.06%
↓ 226.61%
FY20Y/Y Change
Revenue
283.3M
↑ 76.18%
Net Income
-985.5M
↑ 107.05%
Net Profit Margin
-347.93%
↓ 51.87%
FY21Y/Y Change
Revenue
435.1M
↑ 37.08%
Net Income
-1.3B
↑ 20.42%
Net Profit Margin
-305.65%
↑ 42.28%
FY22Y/Y Change
Revenue
416.9M
↓ 4.82%
Net Income
-256.8M
↓ 80.82%
Net Profit Margin
-61.59%
↑ 244.06%
FY23Y/Y Change
Revenue
298.0M
↓ 22.57%
Net Income
-2.4B
↑ 932.67%
Net Profit Margin
-821.42%
↓ 759.83%
Q3 FY22Q/Q Change
Revenue
86.2M
↑ 7.04%
Net Income
-169.6M
↓ 88.89%
Net Profit Margin
-196.76%
↑ 1699.04%
Q4 FY22Q/Q Change
Revenue
74.8M
↓ 14.13%
Net Income
-197.0M
↑ 15.01%
Net Profit Margin
-263.53%
↓ 66.77%
Q1 FY23Q/Q Change
Revenue
64.7M
↓ 13.51%
Net Income
-478.9M
↑ 142.8%
Net Profit Margin
-739.83%
↓ 476.3%
Q2 FY23Q/Q Change
Revenue
82.1M
↑ 24.21%
Net Income
-28.8M
↓ 94.11%
Net Profit Margin
-35.06%
↑ 704.77%
Q3 FY23Q/Q Change
Revenue
82.1M
↓ 24.51%
Net Income
-310.0M
↑ 713.24%
Net Profit Margin
-377.72%
↓ 342.66%
Q4 FY23Q/Q Change
Revenue
78.5M
↓ 4.35%
Net Income
-216.8M
↓ 30.07%
Net Profit Margin
-276.16%
↑ 101.56%
FY18Y/Y Change
Total Assets
1.4B
↑ 112.04%
Total Liabilities
193.6M
↑ 207.91%
FY19Y/Y Change
Total Assets
6.5B
↑ 507.72%
Total Liabilities
1.1B
↑ 669.9%
FY20Y/Y Change
Total Assets
4.9B
↓ 21.46%
Total Liabilities
1.2B
↑ 12.72%
FY21Y/Y Change
Total Assets
5.4B
↓ 0.5%
Total Liabilities
2.5B
↑ 90.59%
FY22Y/Y Change
Total Assets
4.5B
↓ 17.71%
Total Liabilities
1.6B
↓ 38.01%
FY23Y/Y Change
Total Assets
1.8B
↓ 56.56%
Total Liabilities
1.2B
↓ 15.39%
Q3 FY22Q/Q Change
Total Assets
2.5B
↓ 3.28%
Total Liabilities
1.3B
↓ 5.25%
Q4 FY22Q/Q Change
Total Assets
2.2B
↓ 11.23%
Total Liabilities
1.2B
↓ 9.08%
Q1 FY23Q/Q Change
Total Assets
1.8B
↓ 19.24%
Total Liabilities
1.2B
↑ 6.24%
Q2 FY23Q/Q Change
Total Assets
1.7B
↓ 10.19%
Total Liabilities
1.0B
↓ 20.01%
Q3 FY23Q/Q Change
Total Assets
1.7B
↓ 23.84%
Total Liabilities
918.8M
↓ 31.59%
Q4 FY23Q/Q Change
Total Assets
1.4B
↓ 18.49%
Total Liabilities
815.1M
↓ 11.28%
FY18Y/Y Change
Operating Cash Flow
-81.5M
↑ 200.84%
Investing Cash Flow
-223.6M
↑ 1101.93%
Financing Cash Flow
525.8M
↑ 298.07%
FY19Y/Y Change
Operating Cash Flow
-390.0M
↑ 538.62%
Investing Cash Flow
-2.4B
↑ 1343.75%
Financing Cash Flow
4.4B
↑ 1010.05%
FY20Y/Y Change
Operating Cash Flow
-548.8M
↑ 48.44%
Investing Cash Flow
-246.9M
↓ 89.23%
Financing Cash Flow
-40.6M
↓ 100.98%
FY21Y/Y Change
Operating Cash Flow
-370.7M
↓ 39.72%
Investing Cash Flow
-703.7M
↑ 154.31%
Financing Cash Flow
1.0B
↓ 2312.64%
FY22Y/Y Change
Operating Cash Flow
-437.3M
↑ 17.19%
Investing Cash Flow
184.9M
↓ 126.11%
Financing Cash Flow
-36.5M
↓ 103.6%
Q3 FY22Q/Q Change
Operating Cash Flow
-97.6M
↓ 5.06%
Investing Cash Flow
62.6M
↓ 64.76%
Financing Cash Flow
-8.3M
↑ 988.98%
Q4 FY22Q/Q Change
Operating Cash Flow
-106.3M
↑ 7.87%
Investing Cash Flow
99.8M
↑ 57.89%
Financing Cash Flow
-98.6M
↑ 1074.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-103.3M
↓ 2.89%
Investing Cash Flow
105.4M
↑ 5.51%
Financing Cash Flow
93.3M
↓ 194.55%
Q2 FY23Q/Q Change
Operating Cash Flow
-112.3M
↑ 6.39%
Investing Cash Flow
107.7M
↑ 0.0%
Financing Cash Flow
-100.6M
↓ 205.45%

Technicals Summary

Sell

Neutral

Buy

Canopy Growth Corporation is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Canopy Growth Corporation
Canopy Growth Corporation
74.93%
8.91%
-54.62%
-97.64%
-98.54%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.45%
18.72%
28.45%
40.46%
69.87%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.12%
-1.82%
-7.31%
9.45%
9.45%
Zoetis Inc.
Zoetis Inc.
-10.98%
-10.38%
-12.9%
-9.61%
53.43%
Viatris Inc.
Viatris Inc.
-5.61%
18.46%
12.35%
-16.23%
-32.07%
Catalent, Inc.
Catalent, Inc.
0.0%
24.33%
32.98%
-48.49%
27.27%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Canopy Growth Corporation
Canopy Growth Corporation
NA
NA
NA
-3.95
-1.22
-0.09
NA
6.57
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.84
53.84
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.93
28.93
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
29.48
29.48
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.4
222.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Canopy Growth Corporation
Canopy Growth Corporation
Sell
$636.0M
-98.54%
NA
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.4B
69.87%
53.84
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
9.45%
28.93
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$68.5B
53.43%
29.48
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-32.07%
222.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
27.27%
211.02
-31.77%

Institutional Holdings

  • Point72 Asset Management, L.P.

    0.63%
  • Lord, Abbett & Co LLC

    0.62%
  • Susquehanna International Group, LLP

    0.37%
  • JANE STREET GROUP, LLC

    0.34%
  • Mirae Asset Global Investments (Korea) Co Ltd

    0.24%
  • Morgan Stanley - Brokerage Accounts

    0.23%

Corporate Announcements

  • Canopy Growth Corporation Earnings

    Canopy Growth Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

canopy growth corporation is a world-leading diversified cannabis company. we operate a collection of diverse brands and curated strain variety, supported millions of square feet of indoor greenhouse production capacity, partnered with some of the leading names in the sector. here's to future growth.

Organization
Canopy Growth Corporation
Employees
1621
CEO
Mr. David Eric Klein
Industry
Process Industries

FAQs